Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023

Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced the publication of two abstracts regarding MCLA-129 on the European Society for Medical Oncology Asia Congress website.